Remacemide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Remacemide
DrugBank Accession Number
DB06458
Background

Not Available

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 268.36
Monoisotopic: 268.157563272
Chemical Formula
C17H20N2O
Synonyms
  • Remacemide
External IDs
  • AR-R-12924
  • FPL-12924
  • PR-934-423
  • PR-934423A

Pharmacology

Indication

Investigated for use/treatment in epilepsy, huntington's disease, and parkinson's disease.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-BenzodiazepineThe risk or severity of adverse effects can be increased when Remacemide is combined with 1,2-Benzodiazepine.
AbemaciclibThe metabolism of Abemaciclib can be decreased when combined with Remacemide.
AcalabrutinibThe metabolism of Acalabrutinib can be decreased when combined with Remacemide.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Remacemide.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Remacemide.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Remacemide.
AclidiniumRemacemide may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
AgomelatineThe risk or severity of adverse effects can be increased when Remacemide is combined with Agomelatine.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Remacemide.
AlectinibThe metabolism of Alectinib can be decreased when combined with Remacemide.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Remacemide HydrochlorideI1ST2B6HIM111686-79-4HYQMIUSWZXGTCC-UHFFFAOYSA-N

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
EH6763C1IC
CAS number
128298-28-2
InChI Key
YSGASDXSLKIKOD-UHFFFAOYSA-N
InChI
InChI=1S/C17H20N2O/c1-17(19-16(20)13-18,15-10-6-3-7-11-15)12-14-8-4-2-5-9-14/h2-11H,12-13,18H2,1H3,(H,19,20)
IUPAC Name
2-amino-N-(1,2-diphenylpropan-2-yl)acetamide
SMILES
CC(CC1=CC=CC=C1)(NC(=O)CN)C1=CC=CC=C1

References

General References
Not Available
ChemSpider
54551
BindingDB
50239381
ChEBI
91654
ChEMBL
CHEMBL25843
Wikipedia
Remacemide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00895 mg/mLALOGPS
logP2.48ALOGPS
logP2.35ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)13.61ChemAxon
pKa (Strongest Basic)8.14ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area55.12 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity81.01 m3·mol-1ChemAxon
Polarizability30.15 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Spina E, Pisani F, Perucca E: Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin Pharmacokinet. 1996 Sep;31(3):198-214. doi: 10.2165/00003088-199631030-00004. [Article]

Drug created on March 19, 2008 16:34 / Updated on February 21, 2021 18:52